Rocket Pharmaceuticals shares fall 5.07% premarket despite FDA lifting clinical hold on gene therapy trial.

Rocket Pharmaceuticals, Inc. declined 5.07% in premarket trading. The company's stock has been volatile due to recent news regarding the FDA's clinical hold on its gene therapy trial for Danon disease. The FDA lifted the clinical hold, allowing the trial to resume with a revised pre-treatment regime and a lower dose, which initially caused the stock to soar over 30% in morning trading. However, the subsequent decline in premarket trading suggests that investors may be reassessing the long-term implications of the trial's resumption and the potential risks associated with the revised treatment protocol.